金吾财讯 | 摩根士丹利发研指，翰森制药(03692)管理层预计今年产品销售将实现双位数增长，其中创新药将实现25%增长。公司亦迅速向慢性病领域多元化发展，从2027年起将有高价值药物获批。该行表示，公司去年业绩符预期，但阿美乐销售峰值指引上调与今年销售指引带来惊喜，阿美乐高峰销售进一步从60亿元人民币上调至80亿元人民币，并设定今年60亿元人民币销售目标，表明该行先前预估有上望空间，且今年增长将加速。该行上调翰森目标价，由原先24港元升至25港元，维持“增持”评级。
金吾财讯 | 摩根士丹利发研指，翰森制药(03692)管理层预计今年产品销售将实现双位数增长，其中创新药将实现25%增长。公司亦迅速向慢性病领域多元化发展，从2027年起将有高价值药物获批。该行表示，公司去年业绩符预期，但阿美乐销售峰值指引上调与今年销售指引带来惊喜，阿美乐高峰销售进一步从60亿元人民币上调至80亿元人民币，并设定今年60亿元人民币销售目标，表明该行先前预估有上望空间，且今年增长将加速。该行上调翰森目标价，由原先24港元升至25港元，维持“增持”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.